Pancreatic Cancer Research

Clinical trialPhase 1Terminated

A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

A Phase 1a/1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY159 as a Single Agent and In Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Outcome
Stopped earlySponsor business decision. (Business decision)
Phase
Phase 1
Status
Terminated
Study type
Interventional
Start
10 November 2020
Ended
31 August 2023
Enrollment
127 participants
Sites
17
Primary outcomes
Incidence of Adverse Events (AE); Dose Limiting Toxicity of PY159 (Part A only)
Sponsor type
Industry
Results posted
No
Last update
22 March 2024

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This is an open-label, multicenter, First-In-Human (FIH), Phase 1a/1b study of PY159 in subjects with locally advanced (unresectable) and/or metastatic solid tumors that are refractory or relapsed to Standard Of Care (including Checkpoint Inhibitors, if approved for that indication).

Detailed description public domain (ClinicalTrials.gov)

Part A: Dose escalation of PY159 alone and in combination with pembrolizumab in a standard 3+3 design Part B: Dose expansion of one or more dose levels of PY159 administered alone and in combination with pembrolizumab for predefined tumor histology